Health & Environmental Research Online (HERO)


Print Feedback Export to File
7540626 
Journal Article 
Why Great Mitotic Inhibitors Make Poor Cancer Drugs 
Yan, VC; Butterfield, HE; Poral, AH; Yan, MJ; Yang, KL; Pham, C; Muller, FL; , 
2020 
6 
11 
924-941 
English 
32536592 
WOS:000582944600003 
Chemotherapy is central to oncology, perceived to operate only on prolific cancerous tissue. Yet, many non-neoplastic tissues are more prolific compared with typical tumors. Chemotherapies achieve sufficient therapeutic windows to exert antineoplastic activity because they are prodrugs that are bioactivated in cancer-specific environments. The advent of precision medicine has obscured this concept, favoring the development of high-potency kinase inhibitors. Inhibitors of essential mitotic kinases exemplify this paradigm shift, but intolerable on-target toxicities in more prolific normal tissues have led to repeated failures in the clinic. Proliferation rates alone cannot be used to achieve cancer specificity. Here, we discuss integrating the cancer specificity of prodrugs from classical chemotherapeutics and the potency of mitotic kinase inhibitors to generate a class of high-precision cancer therapeutics.